Moderna Stock Soars After $162 Million Profit Reverses Last Year's Loss
Moderna (MRNA) reported Q3 revenue of $1.3B, up 29% YoY, and net income of $162M, reversing last year's loss. The company raised its 2026 revenue growth forecast to 15-25% and expects international markets to contribute about half of annual sales. Shares rose over 15% in premarket trading.
How this was made
The 30-second read
Why it matters
The earnings beat and raised outlook are likely to lift Moderna's stock and may boost sentiment toward other mRNA companies.
Market read
First‑report earnings with profit and guidance raise for a large‑cap biotech, causing a 15% pre‑market surge.
What to watch
Potential regulatory or manufacturing challenges for the upcoming flu vaccine could temper upside.
Background
Moderna's Q3 results mark a turnaround from a loss last year, with overseas COVID‑19 vaccine demand supporting revenue.
Ticker impact
Moderna reported Q3 profit of $162M, revenue $1.3B beating estimates and raised full-year outlook, sending shares up 15% premarket.
upward pressure as investors price in profitability and higher revenue outlook
First report of profit, revenue beat and raised guidance for a large‑cap biotech; market already reacting with a 15% pre‑market jump.
Market effects
Biotech sector may see broader rally on positive earnings momentum.
U.S. markets likely to open higher on the news.
International investors may adjust exposure to vaccine and mRNA platforms.
Counterpoint
Some may argue the profit is modest and future growth depends on uncertain flu and melanoma vaccine launches.
Key entities
- companyModerna
Biotech firm developing mRNA vaccines.
- companyMerck
Partner on personalized melanoma vaccine.
